We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+35.9%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.87B
AUM Growth
+$747M
Cap. Flow
+$514M
Cap. Flow %
7.48%
Top 10 Hldgs %
39.61%
Holding
82
New
19
Increased
22
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$249M
2
MANE
Veradermics Inc
MANE
+$141M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$118M
4
COAG
Hemab Therapeutics
COAG
+$99.4M
5
UTHR icon
United Therapeutics
UTHR
+$69.6M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$182M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$125M
3
AXSM icon
Axsome Therapeutics
AXSM
+$86.7M
4
IMVT icon
Immunovant
IMVT
+$66.6M
5
BBIO icon
BridgeBio Pharma
BBIO
+$62.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
51
MannKind Corp
MNKD
$1.16B
$25.6M 0.37%
+6,000,000
New +$19.5M
IPSC icon
52
Century Therapeutics
IPSC
$360M
$23.2M 0.34%
9,462,645
-25,100
-0.3% -$57.3K
GENB
53
Generate Biomedicines
GENB
$2.08B
$22.5M 0.33%
+1,333,815
New +$18.2M
VSTM icon
54
Verastem
VSTM
$664M
$21.9M 0.32%
5,740,850
– –
KURA icon
55
Kura Oncology
KURA
$1.01B
$21.7M 0.32%
1,978,565
-664,977
-25% -$6.27M
ENTA icon
56
Enanta Pharmaceuticals
ENTA
$375M
$21.1M 0.31%
1,444,167
-512,700
-26% -$6.89M
NKTR icon
57
Nektar Therapeutics
NKTR
$2.29B
$20.9M 0.3%
+300,000
New +$22M
OLMA icon
58
Olema Pharmaceuticals
OLMA
$843M
$18.8M 0.27%
+1,500,000
New +$20.1M
KLRA
59
Kailera Therapeutics
KLRA
$1.73B
$15.4M 0.22%
+700,000
New +$15.4M
KARD
60
Kardigan Inc
KARD
$1.72B
$14.3M 0.21%
+600,000
New +$13.9M
ELVN icon
61
Enliven Therapeutics
ELVN
$3.73B
$11.4M 0.17%
+225,000
New +$9.55M
PMN icon
62
ProMIS Neurosciences
PMN
$116M
$11M 0.16%
835,655
– –
IMCR icon
63
Immunocore
IMCR
$1.61B
$9.88M 0.14%
311,218
-1,620,666
-84% -$47.9M
XNCR icon
64
Xencor
XNCR
$1.77B
$9.56M 0.14%
+593,551
New +$7.41M
CNTX icon
65
Context Therapeutics
CNTX
$34.7M
$4.11M 0.06%
7,419,355
– –
IVA
66
Inventiva
IVA
$891M
$3.02M 0.04%
800,000
-422,453
-35% -$2.03M
ALGS icon
67
Aligos Therapeutics
ALGS
$31.5M
$2.56M 0.04%
444,110
– –
ANIP icon
68
ANI Pharmaceuticals
ANIP
$1.67B
– –
-600,000
Closed -$46.1M
APGE
69
DELISTED
Apogee Therapeutics
APGE
– –
-285,000
Closed -$24M
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
– –
-4,532,374
Closed -$182M
BBIO icon
71
BridgeBio Pharma
BBIO
$13.5B
– –
-841,445
Closed -$62.5M
CNTA
72
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-3,158,041
Closed -$125M
HELP
73
Cybin Inc
HELP
$975M
– –
-1,313,137
Closed -$6.3M
ENGN icon
74
enGene Therapeutics
ENGN
$127M
– –
-4,377,572
Closed -$29.8M
GERN icon
75
Geron
GERN
$835M
– –
-31,720,278
Closed -$47.3M
1 2
3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Deep Track Capital held 82 positions worth $6.87B, up 12% from $6.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Deep Track Capital deployed $514M of net new capital in Q2 2026, opening 19 new positions and adding to 22 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 825,000 shares worth $248M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $86.7M trimmed.

  • Deep Track Capital's largest Q2 2026 buy was Alnylam Pharmaceuticals: 825,000 shares worth $248M.
  • Deep Track Capital added most to Veradermics Inc in Q2 2026, an estimated $141M increase.
  • Deep Track Capital's biggest Q2 2026 reduction was Axsome Therapeutics, cutting an estimated $86.7M.
  • Deep Track Capital fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $182M.
  • Deep Track Capital's ten largest holdings make up 40% of its $6.87B portfolio in Q2 2026.
  • Deep Track Capital opened 19 new positions and closed 15 in Q2 2026.
  • Deep Track Capital's portfolio value rose 12% quarter-over-quarter to $6.87B.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.